Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Carboplatin + Durvalumab + Paclitaxel & Endometrial cancer (EC) (MMR-d/MSI-H), on June 14, 2024, the Food and Drug Administration approved Carboplatin + Durvalumab + Paclitaxel followed by single-agent durvalumab for adult patients with primary advanced or recurrent Endometrial cancer (EC) (MMR-d/MSI-H) (1)
EMA has approved Carboplatin + Durvalumab + Paclitaxel for first‑line advanced or recurrent endometrial cancer, including dMMR/MSI‑H disease, with maintenance therapy tailored to MMR status (2, 3)
#…